Induction of vascular networks in adult organs: Implications to proangiogenic therapy

Annals of the New York Academy of Sciences

Volumn 995, Issue , 2003, Pages 208-216

  Dor, Yuval ^a   Djonov, Valentin ^b   Keshet, Eli ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Angiogenesis; Conditional transgenic; Therapy; VEGF

Indexed keywords

VASCULOTROPIN;

ANALYTIC METHOD; ANGIOGENESIS; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; GENE SWITCHING; HEART MUSCLE; HEMANGIOMA; HEMODYNAMICS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STEM CELL; TRANSGENIC MOUSE; WATER CONTENT;

ANIMALIA; MUS MUSCULUS;

EID: 0038806411     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb03224.x     Document Type: Conference Paper

References (16)

1. CHILDS, S. et al. 2002. Patterning angiogenesis in the zebrafish embryo. Development 129: 973-982.
2. LEE, S.H. et al. 2001. Inhibition of angiogenesis by mouse sprouty protein. J. Biol. Chem. 276: 4123-4133.
3. DOR, Y. & E. KESHET. 1997. Ischemia-driven angiogenesis. Trends Cardiovasc. Med. 7: 289-294.
4. VAN ROYEN, N. et al. 2001. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc. Res. 49: 543-553.
5. CARMELIET, P. et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
6. FERRARA, N. et al. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.
7. Yu, Z., C.S. REDFERN & G.I. FISHMAN. 1996. Conditional transgene expression in the heart. Circ. Res. 79: 691-697.
8. KISTNER, A. et al. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. USA 93: 10933-10938.
9. MAYFORD, M. et al. 1996. Control of memory formation through regulated expression of a CaMKII transgene. Science 274: 1678-1683.
10. DOR, Y. et al. 2001. A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development 128: 1531-1538.
11. DOR, Y. et al. 2002. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21: 1939-1947.
12. RAFII, S. et al. 2002. Vascular and hematopoietic stem cells: novel targets for antiangiogenic therapy? Nat. Rev. Cancer 2: 826-835.
13. ALON, T. et al. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1: 1024-1028.
14. BENJAMIN, L.E. & E. KESHET. 1997. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA 94: 8761-8766.
15. LINDAHL, P. et al. 1997. Pericyte loss and microaneurism formation in PDGF-B-deficient mice. Science 277: 242-245.
16. BENJAMIN, L. et al. 1999. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103: 159-165.